Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease
نویسندگان
چکیده
منابع مشابه
Infliximab treatment for steroid-refractory acute graft-versus-host disease.
BACKGROUND AND OBJECTIVES Tumor necrosis factor a is one of the principal cytokines involved in the pathogenesis of acute graft-versus-host-disease (GVHD). Infliximab is an antibody to this cytokine. DESIGN AND METHODS We performed a retrospective analysis to evaluate the activity of infliximab in 32 patients with severe steroid-refractory acute GVHD. The patients received a median of 3 weekl...
متن کاملInterleukin 7 worsens graft-versus-host disease.
Impaired immune reconstitution has moved to the forefront of clinical problems limiting progress in allogeneic bone marrow transplantation (BMT). The identification of therapies that can enhance immune reconstitution by increasing thymopoiesis is critical to solving this problem. Interleukin 7 (IL-7) is the most potent thymopoietic cytokine identified thus far. To study the effects of IL-7 on i...
متن کاملFecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut.
Increasing evidence indicates that the gut microbiota is closely associated with acute graft-versus-host disease (aGVHD) in stem cell transplantation (SCT). Fecal microbiota transplantation (FMT) could represent an alternative treatment option for aGVHD. However, FMT for SCT patients carries a potential risk of infection by infused microbiota because of the severely immunosuppressed status. We ...
متن کاملIntramesenteric Steroid Treatment for Steroid- Refractory Gastrointestinal Graft Versus Host Disease
UNLABELLED Currently, steroid-refractory severe gastrointestinal (GI) graft versus host disease (GVHD) is among the most important complications of allogeneic transplantation, and as yet there is no standard approach to its treatment. Herein we report two cases with steroid-refractory GI GVHD that received intramesenteric steroid treatment. In both cases the frequency and volume of diarrhea res...
متن کاملResponse of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1.
Therapy of steroid-resistant graft-versus-host disease (GVHD) with antibodies to T cells or cytokines is of limited value because GVHD is mediated by a pleomorphic group of effective cells and cytokines. CBL-1, a murine monoclonal antibody, recognises an antigen on activated T cells, B cells, and natural killer cells. We administered CBL-1 to ten patients with grade III or IV steroid-resistant ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Blood
سال: 1994
ISSN: 0006-4971,1528-0020
DOI: 10.1182/blood.v84.4.1342.1342